Financhill
Buy
60

GH Quote, Financials, Valuation and Earnings

Last price:
$101.39
Seasonality move :
10.65%
Day range:
$101.50 - $104.75
52-week range:
$29.91 - $112.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.16x
P/B ratio:
32.59x
Volume:
1M
Avg. volume:
2.2M
1-year change:
228.28%
Market cap:
$13.4B
Revenue:
$739M
EPS (TTM):
-$3.21

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GH
Guardant Health, Inc.
$235.7M -$0.49 32.68% -47.37% $114.05
DGX
Quest Diagnostics, Inc.
$2.7B $2.50 5.05% 21.08% $198.06
EXAS
EXACT Sciences Corp.
$810.6M $0.16 20.65% -84.17% $104.56
ILMN
Illumina, Inc.
$1.1B $1.17 -0.1% 4.82% $125.28
NTRA
Natera, Inc.
$514.8M -$0.35 21.14% -42.93% $246.26
WGS
GeneDx Holdings Corp.
$104.7M $0.42 25.98% -44.8% $170.89
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GH
Guardant Health, Inc.
$102.98 $114.05 $13.4B -- $0.00 0% 14.16x
DGX
Quest Diagnostics, Inc.
$175.94 $198.06 $19.6B 20.65x $0.80 1.79% 1.83x
EXAS
EXACT Sciences Corp.
$101.57 $104.56 $19.2B -- $0.00 0% 6.18x
ILMN
Illumina, Inc.
$134.95 $125.28 $20.6B 30.23x $0.00 0% 4.96x
NTRA
Natera, Inc.
$233.74 $246.26 $32.6B -- $0.00 0% 14.90x
WGS
GeneDx Holdings Corp.
$133.79 $170.89 $3.9B 2,218.74x $0.00 0% 9.54x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GH
Guardant Health, Inc.
136.47% 1.840 16.98% 2.94x
DGX
Quest Diagnostics, Inc.
46.79% 0.203 30.05% 0.90x
EXAS
EXACT Sciences Corp.
50.33% 1.709 24.46% 2.24x
ILMN
Illumina, Inc.
51.97% 2.433 17.73% 1.04x
NTRA
Natera, Inc.
13.7% 1.342 0.9% 3.03x
WGS
GeneDx Holdings Corp.
28.13% 1.613 3.68% 2.47x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GH
Guardant Health, Inc.
$171.6M -$99M -36.05% -8518.58% -37.33% -$45.8M
DGX
Quest Diagnostics, Inc.
$911M $420M 7.41% 14.33% 14.92% $419M
EXAS
EXACT Sciences Corp.
$583.9M $16.3M -18.87% -38% 1.91% $190M
ILMN
Illumina, Inc.
$732M $231M 14.3% 30.55% 21.33% $253M
NTRA
Natera, Inc.
$384.4M -$97.6M -21.88% -26.6% -16.48% $24.5M
WGS
GeneDx Holdings Corp.
$79.4M -$3.1M 0.56% 0.82% -2.68% $9.6M

Guardant Health, Inc. vs. Competitors

  • Which has Higher Returns GH or DGX?

    Quest Diagnostics, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of 9.13%. Guardant Health, Inc.'s return on equity of -8518.58% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health, Inc.
    64.71% -$0.74 $971.9M
    DGX
    Quest Diagnostics, Inc.
    32.35% $2.15 $13.8B
  • What do Analysts Say About GH or DGX?

    Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 10.75%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $198.06 which suggests that it could grow by 12.57%. Given that Quest Diagnostics, Inc. has higher upside potential than Guardant Health, Inc., analysts believe Quest Diagnostics, Inc. is more attractive than Guardant Health, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health, Inc.
    17 0 0
    DGX
    Quest Diagnostics, Inc.
    7 10 0
  • Is GH or DGX More Risky?

    Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.214%.

  • Which is a Better Dividend Stock GH or DGX?

    Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.79% to investors and pays a quarterly dividend of $0.80 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GH or DGX?

    Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. Guardant Health, Inc.'s net income of -$92.7M is lower than Quest Diagnostics, Inc.'s net income of $257M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Quest Diagnostics, Inc.'s PE ratio is 20.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.16x versus 1.83x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health, Inc.
    14.16x -- $265.2M -$92.7M
    DGX
    Quest Diagnostics, Inc.
    1.83x 20.65x $2.8B $257M
  • Which has Higher Returns GH or EXAS?

    EXACT Sciences Corp. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of -2.3%. Guardant Health, Inc.'s return on equity of -8518.58% beat EXACT Sciences Corp.'s return on equity of -38%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health, Inc.
    64.71% -$0.74 $971.9M
    EXAS
    EXACT Sciences Corp.
    68.64% -$0.10 $5B
  • What do Analysts Say About GH or EXAS?

    Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 10.75%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $104.56 which suggests that it could grow by 2.95%. Given that Guardant Health, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Guardant Health, Inc. is more attractive than EXACT Sciences Corp..

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health, Inc.
    17 0 0
    EXAS
    EXACT Sciences Corp.
    3 18 0
  • Is GH or EXAS More Risky?

    Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.

  • Which is a Better Dividend Stock GH or EXAS?

    Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GH or EXAS?

    Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Guardant Health, Inc.'s net income of -$92.7M is lower than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.16x versus 6.18x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health, Inc.
    14.16x -- $265.2M -$92.7M
    EXAS
    EXACT Sciences Corp.
    6.18x -- $850.7M -$19.6M
  • Which has Higher Returns GH or ILMN?

    Illumina, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of 13.85%. Guardant Health, Inc.'s return on equity of -8518.58% beat Illumina, Inc.'s return on equity of 30.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health, Inc.
    64.71% -$0.74 $971.9M
    ILMN
    Illumina, Inc.
    67.59% $0.97 $5B
  • What do Analysts Say About GH or ILMN?

    Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 10.75%. On the other hand Illumina, Inc. has an analysts' consensus of $125.28 which suggests that it could fall by -7.17%. Given that Guardant Health, Inc. has higher upside potential than Illumina, Inc., analysts believe Guardant Health, Inc. is more attractive than Illumina, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health, Inc.
    17 0 0
    ILMN
    Illumina, Inc.
    7 8 1
  • Is GH or ILMN More Risky?

    Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.845%.

  • Which is a Better Dividend Stock GH or ILMN?

    Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GH or ILMN?

    Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. Guardant Health, Inc.'s net income of -$92.7M is lower than Illumina, Inc.'s net income of $150M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 30.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.16x versus 4.96x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health, Inc.
    14.16x -- $265.2M -$92.7M
    ILMN
    Illumina, Inc.
    4.96x 30.23x $1.1B $150M
  • Which has Higher Returns GH or NTRA?

    Natera, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of -14.78%. Guardant Health, Inc.'s return on equity of -8518.58% beat Natera, Inc.'s return on equity of -26.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health, Inc.
    64.71% -$0.74 $971.9M
    NTRA
    Natera, Inc.
    64.91% -$0.64 $1.5B
  • What do Analysts Say About GH or NTRA?

    Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 10.75%. On the other hand Natera, Inc. has an analysts' consensus of $246.26 which suggests that it could grow by 5.36%. Given that Guardant Health, Inc. has higher upside potential than Natera, Inc., analysts believe Guardant Health, Inc. is more attractive than Natera, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health, Inc.
    17 0 0
    NTRA
    Natera, Inc.
    12 2 0
  • Is GH or NTRA More Risky?

    Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.628, suggesting its more volatile than the S&P 500 by 62.801%.

  • Which is a Better Dividend Stock GH or NTRA?

    Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GH or NTRA?

    Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Natera, Inc. quarterly revenues of $592.2M. Guardant Health, Inc.'s net income of -$92.7M is lower than Natera, Inc.'s net income of -$87.5M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.16x versus 14.90x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health, Inc.
    14.16x -- $265.2M -$92.7M
    NTRA
    Natera, Inc.
    14.90x -- $592.2M -$87.5M
  • Which has Higher Returns GH or WGS?

    GeneDx Holdings Corp. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of -6.54%. Guardant Health, Inc.'s return on equity of -8518.58% beat GeneDx Holdings Corp.'s return on equity of 0.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health, Inc.
    64.71% -$0.74 $971.9M
    WGS
    GeneDx Holdings Corp.
    68.04% -$0.27 $406.6M
  • What do Analysts Say About GH or WGS?

    Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 10.75%. On the other hand GeneDx Holdings Corp. has an analysts' consensus of $170.89 which suggests that it could grow by 27.73%. Given that GeneDx Holdings Corp. has higher upside potential than Guardant Health, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Guardant Health, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health, Inc.
    17 0 0
    WGS
    GeneDx Holdings Corp.
    7 1 0
  • Is GH or WGS More Risky?

    Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison GeneDx Holdings Corp. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.538%.

  • Which is a Better Dividend Stock GH or WGS?

    Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeneDx Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. GeneDx Holdings Corp. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GH or WGS?

    Guardant Health, Inc. quarterly revenues are $265.2M, which are larger than GeneDx Holdings Corp. quarterly revenues of $116.7M. Guardant Health, Inc.'s net income of -$92.7M is lower than GeneDx Holdings Corp.'s net income of -$7.6M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while GeneDx Holdings Corp.'s PE ratio is 2,218.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.16x versus 9.54x for GeneDx Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health, Inc.
    14.16x -- $265.2M -$92.7M
    WGS
    GeneDx Holdings Corp.
    9.54x 2,218.74x $116.7M -$7.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is CoreWeave Stock Down So Much?
Why Is CoreWeave Stock Down So Much?

AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…

Why Did Stan Druckenmiller Buy MercadoLibre Stock?
Why Did Stan Druckenmiller Buy MercadoLibre Stock?

In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
72
GLTO alert for Dec 29

Galecto, Inc. [GLTO] is down 12.13% over the past day.

Sell
20
SMX alert for Dec 29

SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.

Sell
11
CDNAF alert for Dec 29

Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock